GLAXOSMITHKLINE PLC Form 6-K August 03, 2009

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending August 2009

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary shares of GlaxoSmithKline plc in respect of the under-mentioned person:

Mr A P Witty acquired a beneficial interest in 735 Ordinary shares arising from the re-investment of dividends on 31 July 2009 at £11.486 per share.

He also exercised an award over 10,665 Ordinary shares under the Company's Annual Incentive Plan on 31 July 2009 and sold 4,388 at a price of £11.55125 on 3 August to meet the tax liability arising from this exercise.

The Company and the above named individual were advised of this transaction on 3 August 2009.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bickell Company Secretary

3 August 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GlaxoSmithKline plc	
(Registrant)	

Date: August 03 2009

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc